Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity

Journal of Medicinal Chemistry

Volumn 58, Issue 1, 2015, Pages 433-442

  Premnath, Padmavathy Nandha ^a   Craig, Sandra N ^a   Liu, Shu ^a,c   Anderson, Erin L ^a   Grigoroudis, Asterios I ^b   Kontopidis, George ^b   Perkins, Tracy L ^a   Wyatt, Michael D ^a   Pittman, Douglas L ^a   McInnes, Campbell ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF THESSALY   (Greece)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE DERIVATIVE; CITRULLINE; CYCLIN A; CYCLIN A2; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; LEUCINE; OCTAPEPTIDE; PENTAPEPTIDE; PHENYLALANINE DERIVATIVE; PROTEIN P107; PEPTIDE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ALKYLATION; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL VIABILITY; COMPETITIVE BINDING ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; LIPOPHILICITY; METABOLIC STABILITY; METHYLATION; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; U2OS CELL LINE; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937119704     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5015023     Document Type: Article

References (31)

1. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment J. Clin. Oncol. 2006, 24, 1770-1783
2. Sherr, C. J. Cancer cell cycles Science 1996, 274, 1672-1677
3. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer Nat. Rev. Cancer 2001, 1, 222-231
4. WAF1 Curr. Biol. 1997, 7, 71-80
5. Chen, J. S. P.; Kornbluth, S.; Dynlacht, B. D.; Dutta, A. Cyclin-binding motifs are essential for the function of p21CIP1 Mol. Cell. Biol. 1996, 16, 4673-4682
6. Kitagawa, M.; Higashi, H.; Suzuki-Takahashi, I.; Segawa, K.; Hanks, S. K.; Taya, Y.; Nishimura, S.; Okuyama, A. Phosphorylation of E2F-1 by cyclin A-cdk2 Oncogene 1995, 10, 229-236
7. Phillips, A. C.; Vousden, K. H. E2F-1 induced apoptosis Apoptosis 2001, 6, 173-182
8. Chen, Y. N.; Sharma, S. K.; Ramsey, T. M.; Jiang, L.; Martin, M. S.; Baker, K.; Adams, P. D.; Bair, K. W.; Kaelin, W. G., Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4325-4329
9. Mendoza, N.; Fong, S.; Marsters, J.; Koeppen, H.; Schwall, R.; Wickramasinghe, D. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth Cancer Res. 2003, 63, 1020-1024
10. Mendoza, N.; Severin, C.; Marsters, J.; Wickramasinghe, D. Cyclin A antagonists kill tumor cells in vitro and in vivo Proc. Am. Assoc. Cancer Res. 2004, 45, 834
11. Tetsu, O.; McCormick, F. Proliferation of cancer cells despite CDK2 inhibition Cancer Cell 2003, 3, 233-245
12. Malumbres, M.; Barbacid, M. Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 2006, 9, 2-4
13. Malumbres, M.; Sotillo, R.; Santamaria, D.; Galan, J.; Cerezo, A.; Ortega, S.; Dubus, P.; Barbacid, M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6 Cell 2004, 118, 493-504
14. Lam, L. T.; Pickeral, O. K.; Peng, A. C.; Rosenwald, A.; Hurt, E. M.; Giltnane, J. M.; Averett, L. M.; Zhao, H.; Davis, R. E.; Sathyamoorthy, M.; Wahl, L. M.; Harris, E. D.; Mikovits, J. A.; Monks, A. P.; Hollingshead, M. G.; Sausville, E. A.; Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol Genome Biol. 2001, 2, research0041.1-0041.11
15. Lu, X.; Burgan, W. E.; Cerra, M. A.; Chuang, E. Y.; Tsai, M. H.; Tofilon, P. J.; Camphausen, K. Transcriptional signature of flavopiridol-induced tumor cell death Mol. Cancer Ther 2004, 3, 861-872
16. WAF1 derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A J. Pept. Res. 2002, 60, 257-270
17. McInnes, C.; Andrews, M. J.; Zheleva, D. I.; Lane, D. P.; Fischer, P. M. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit Curr. Med. Chem.: Anti-Cancer Agents 2003, 3, 57-69
18. Liu, S.; Premnath, P. N.; Bolger, J. K.; Perkins, T. L.; Kirkland, L. O.; Kontopidis, G.; McInnes, C. Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly J. Med. Chem. 2013, 56, 1573-1582
19. McInnes, C. Progress in the development of non-ATP competitive protein kinase inhibitors for oncology. In Annual Reports in Medicinal Chemistry; Bernstein, P; Desai, M., Ed.; Elsevier: Amsterdam, 2012; Vol. 47, pp 459-474.
20. Andrews, M. J.; Kontopidis, G.; McInnes, C.; Plater, A.; Innes, L.; Cowan, A.; Jewsbury, P.; Fischer, P. M. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors ChemBioChem 2006, 7, 1909-1915
21. Premnath, P. N.; Liu, S.; Perkins, T.; Abbott, J.; Anderson, E.; McInnes, C. Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors Bioorg. Med. Chem. 2014, 22, 616-622
22. Liu, S.; Bolger, J. K.; Kirkland, L. O.; Premnath, P. N.; McInnes, C. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements ACS Chem. Biol. 2010, 5, 1169-1182
23. Kontopidis, G.; Andrews, M. J. I.; McInnes, C.; Cowan, A.; Powers, H.; Innes, L.; Plater, A.; Griffiths, G.; Paterson, D.; Zheleva, D. I.; Lane, D. P.; Green, S.; Walkinshaw, M. D.; Fischer, P. M. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange Structure 2003, 11, 1537-1546
24. Castanedo, G.; Clark, K.; Wang, S.; Tsui, V.; Wong, M.; Nicholas, J.; Wickramasinghe, D.; Marsters, J. C., Jr.; Sutherlin, D. CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads Bioorg. Med. Chem. Lett. 2006, 16, 1716-1720
25. Kontopidis, G.; Andrews, M. J.; McInnes, C.; Plater, A.; Innes, L.; Renachowski, S.; Cowan, A.; Fischer, P. M. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design ChemMedChem 2009, 4, 1120-1128
26. Kennedy, K. J.; Lundquist, J. T. I.; Simandan, T. L.; Kokko, K. P.; Beeson, C. C.; Dix, T. A. Design rationale, synthesis, and characterization of non-natural analogs of the cationic amino acids arginine and lysine J. Pept. Res. 2000, 55, 348-358
27. Chatterjee, J.; R, F.; Kessler, H. N-methylation of peptides and proteins: an important element for modulating biological functions Angew. Chem., Int. Ed. 2013, 52, 254-269
28. Khandogin, J.; Brooks, C. L., 3rd. Constant pH molecular dynamics with proton tautomerism Biophys. J. 2005, 89, 141-157
29. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 1986, 89, 271-277
30. Andrews, M. J.; McInnes, C.; Kontopidis, G.; Innes, L.; Cowan, A.; Plater, A.; Fischer, P. M. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes Org. Biomol. Chem. 2004, 2, 2735-2741
31. Papaneophytou, C. P.; Grigoroudis, A. I.; McInnes, C.; Kontopidis, G. Quantification of the effects of ionic strength, viscosity, and hydrophobicity on protein-ligand binding affinity ACS Med. Chem. Lett. 2014, 5, 931-936